Vlad Coric, Biohaven CEO
A pair of storied neuroscience biotechs looks to raise nearly $450M combined (and maybe more) via public offerings
In late September, Biogen and Eisai blew life back into the amyloid hypothesis with a successful readout of their Phase III study on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
